Rapport Therapeutics, Inc. (RAPP) Stock Statistics & Valuation Metrics

Rapport Therapeutics, Inc. has a market cap or net worth of $1.89B. The enterprise value is $1.37B.

Rapport Therapeutics, Inc. has 47,826,927 shares outstanding. The number of shares has decreased by -2.65% in one year.

Rapport Therapeutics, Inc.’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -25.21%.

The current PE Ratio of Rapport Therapeutics, Inc. is ―. Rapport Therapeutics, Inc.’s PEG ratio is 0.53.

In the last 12 months, Rapport Therapeutics, Inc. had revenue of 0.00 and earned -111.48M in profits. Earnings per share was -2.86.

In the last 12 months, operating cash flow was -80.30M and capital expenditures -242.00K, giving a free cash flow of -80.54M billion.

Rapport Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Rapport Therapeutics, Inc. upcoming earnings date is Aug 6, 2026, Before Open (Confirmed).

Rapport Therapeutics, Inc. as a current ratio of 26.17, with Debt / Equity ratio of 2.29%

In the past 12 months, Rapport Therapeutics, Inc. has paid 0.00 in taxes.

Rapport Therapeutics, Inc. EV to EBITDA ratio is -11.16, with an EV/FCF ratio of -15.71.

Rapport Therapeutics, Inc. has $476.78M in cash and marketable securities with $10.80M in debt, giving a net cash position of $465.98M billion.

Gross margin is 97.54%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Rapport Therapeutics, Inc. is $53.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy